Orphan Drugs Market Access

Prices Are Standing In The Way Of Patients

In Market Access by poppy

A New Study Released By Tufts Reveals The Challenges For Patients

A new study released by Tufts center for the Study of Drug Development at the Tufts University has revealed that despite the increasing pace of approvals for new orphan drugs (in the US and Europe) over the past 14 years, these drugs are in fact becoming much harder for patients to get hold of.

Between 2000 and 2013 the number of orphan drugs approved in the US was 86, up from 65 during the 18 years prior (1983-2000).

In Europe however 96 orphan drugs were approved, more than double the 44 from the period prior to this (1983-2000).

Orphan drugs are developed for conditions that affect less than 200,000 people in the US, or 5 per 10,000 or fewer in the EU.

Challenges Orphan drugs face in the US relative to Europe, are higher cost sharing by patients, which means increased levels of non-compliance.

“In 2013 nine Orphan drugs were approved in the US, the most in a single year”

Joshua Cohen, Assistant professor at Tufts CSDD said ” More Orphan drugs are in development today than ever before, more receiving market approval, in 2013 nine orphan drugs were approved in the US, the most in a single year. But the high cost of these medicines is leading insurers to reassess reimbursement policies more out of pocket costs for patients.”

Currently the most expensive orphan drug can cost more than half a million dollars per year per patient in the US.